Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital and Institute, Beijing, China
Auto-generated profile, based on publicly available information
Tian Gao
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital and Institute, Beijing, China
Purpose: Alveolar soft part sarcoma (ASPS) is an ultrarare soft-tissue sarcoma with a high rate of metastasis and no established treatment. This study aimed to explore the efficacy and safety of anlotinib (a tyrosine kinase inhibitor) and TQB2450 (a PD-L1 inhibitor) in patients with ASPS. Patients and Methods: This single-arm, phase II study evaluated the efficacy of TQB2450, an anti–PD-L1 agent, combined with anlotinib, a tyrosine kinase inhibitor, in adults with advanced ASPS. TQB2450 was given intravenously (1,200 mg) on day 1, and anlotinib (12 mg/day) was taken orally from day 1 to 14 every 3 weeks. The primary endpoint was overall response rate, with secondary endpoints including duration of response, progression-free survival, and overall survival. Lymphocyte infiltration and tertiary lymphoid structure (TLS) were also analyzed as potential prognostic biomarkers. Results: The study enrolled 29 patients, of whom 28 were evaluable (one withdrew because of acute pancreatitis). An objective response was achieved in 82.1% of patients, including 4 complete and 19 partial responses. The median time to response was 2.8 months, and the duration of response was not reached, with an estimated median progression-free survival of 35.2 months. Grade 3 to 4 treatment-related adverse events occurred in 44.8% of patients, with no study-related deaths. Responders had a higher proportion of TLS area, TLS density, and CD20-positive immune cells. Conclusions: The combination of anlotinib and TQB2450 is effective and tolerable in patients with ASPS. TLS may serve as a prognostic biomarker, meriting further investigation.
Purpose: Alveolar soft part sarcoma (ASPS) is an ultrarare soft tissue sarcoma. Current standard therapy with PD-1/PD-L1 inhibitors achieves limited response rates (<40%). Lymphocyte-activation gene 3 (LAG-3) is coexpressed with PD-1 on exhausted T cells, and dual blockade has shown synergy in some solid tumors but remains unexplored in sarcoma. This trial evaluated the efficacy of IBI110 (anti–LAG-3) plus sintilimab (anti–PD-1) in advanced ASPS. Patients and Methods: This open-label, phase II study enrolled 28 patients from July 2022 to September 2023 (median follow-up, 33.6 months). Both drugs were given intravenously at 200 mg every 3 weeks. The primary endpoint was overall response rate (ORR) by RECIST v1.1. Results: Among 28 patients, 8 (28.6%) were resistant to prior immune checkpoint inhibitors (ICI), and 20 (71.4%) were ICI-naïve. The overall ORR was 51.8% (14/27 evaluable), including 4 complete responses and 10 partial responses. During a median follow-up of 33.6 months, the median progression-free survival (PFS) and overall survival (OS) were not reached in the whole population. In ICI-naïve patients, the ORR was 60%, with median PFS/OS not reached. In ICI-resistant patients, the ORR was 25%, with median PFS of 14.9 months and median OS of 25.4 months. The median time to response was 3.3 months; the median duration of response (DoR) was not reached. Grade 3 to 4 treatment-related adverse events occurred in nine patients (32.1%), with no treatment-related deaths. Exploratory analysis showed that responders had significantly higher baseline LAG-3+ cell density in tumor specimens. Conclusions: Dual LAG-3/PD-1 blockade demonstrated promising and durable antitumor activity with manageable safety in both ICI-naïve and ICI-resistant advanced ASPS, warranting further investigation.